CTRI/2014/11/005171已完成3 期
A Double Blind, Randomized, Active Controlled, Parallel Design, Comparative PK, Efficacy, Safety and Immunogenicity Study of Bmab-100 and Avastin®, both in Combination with XELOX Chemotherapy in Patients with Metastatic Colorectal Cancer - mCRC
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female patients aged 18 years and above
- •2. Histopathologically confirmed colorectal cancer.
- •3. Diagnosis of metastatic colorectal cancer which is not amenable to curative surgery and/or radiation
- •4. Part I of the study will include only patients who have received chemotherapy earlier for metastatic colorectal cancer [i.e. at least 1st line treatment failure mCRC patients]. Part II of the study will include only patients who have not received any treatment for metastatic colorectal cancer [i.e. only 1st line mCRC patients]
- •5. Measurable disease on radiological assessment according to RECIST 1.1 criteria
- •6. Patient is an eligible candidate for XELOX [capecitabine and oxaliplatin] chemotherapy and not suitable for surgery.
- •7. ECOG status 0 or 1 for part I of the study and ECOG status 0, 1 or 2 for part II of the study.
- •8. Have life expectancy of at least 4 months as per the investigator.
- •9. Women of childbearing potential and men must be using two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.) for the entire duration of the study from the time of screening and 4 months following the completion of therapy.
排除标准
- •1. Received prior chemotherapy for metastatic disease [chemotherapy for primary disease is acceptable] which is applicable for part II of the study only.
- •2. Prior treatment with bevacizumab
- •3. History of hemoptysis, thrombotic or hemorrhagic event in past 6 months
- •4. Therapeutic anticoagulation; regular use of aspirin (325 mg/day), NSAIDs or agents known to inhibit platelet function
- •5. Radiation therapy for metastatic disease or surgery within 1 month of randomization
- •6. Serious non-healing wound or bone fracture
- •7. Known hypersensitivity to bevacizumab, capecitabine or oxaliplatin
- •8. Uncontrolled hypertension [defined as either systolic blood pressure 150 mm of Hg or diastolic blood pressure 100 mm of Hg]
- •9. Urine protein on dipstick analysis >= 2+ [If urine protein is >=2+, further assessments should show urine protein:creatinine ratio 0.5 grams protein per gram creatinine by urinalysis OR total urinary protein 1,000 mg by 24-hour urine collection for inclusion]
- •10. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •11. High levels of SGOT 3 x ULN and 5 x ULN in patients with liver metastasis. Serum bilirubin 1.5 X ULN.
- •12. Hemoglobin 9 gm/dl or platelets 100,000/μl (with no blood and/ or packed cell transfusion within 2 weeks).
- •13. Patients with known or suspected brain metastases. Patients with a history of CNS metastases are eligible if they have been successfully treated and are off steroids for at least 4 weeks before randomization.
- •14. Patients with history of prior malignancy other than colorectal cancer.
- •15. Other invasive malignancy within the past 5 years except nonmelanoma skin cancer and successfully treated cervical carcinoma in situ.
- •16. Patients with severe renal impairment (estimated creatinine clearance below 30 mL/min)
- •17. Patients with clinically significant or poorly controlled co-morbid conditions like endocrinological, renal, hepatic, cardiac, pulmonary, hematological, gastrointestinal, neurological or psychological disorder, which in the opinion of the investigator may jeopardize the safety of the patient during the study or may interfere with the evaluation of efficacy of the study medication.
- •18. Patient in the opinion of investigator is not capable of complying with study requirements.
- •19. Patients with current history of drug/alcohol abuse.
- •20. Patient is unable or unwilling to give a written informed consent.
- •21. Patient has participated in an investigational drug study within last one month.
研究者
相似试验
已完成
3 期
A clinical study to compare the Efficacy, Safety and Tolerability of FDC of Dapagliflozin 10 mg plus Linagliptin 5mg tablets versus FDC of Dapagliflozin 10 mg plus Vildagliptin SR 100 mg Tablets in patients with Type 2 Diabetes MellitusCTRI/2022/07/044179Micro Labs Limited229
进行中（未招募）
1 期
A Phase 3 study to compare the efficacy and safety of CT-P39 to Xolair in Patients With Chronic Spontaneous Urticaria who have symptoms despite H1-antihistamine TreatmentChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000952-36-BGCELLTRION, Inc.600
进行中（未招募）
1 期
A Phase 3 study to compare the efficacy and safety of CT-P39 to Xolair in Patients With Chronic Spontaneous Urticaria who have symptoms despite H1-antihistamine TreatmentChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000952-36-HUCELLTRION, Inc.600
进行中（未招募）
1 期
Study of Paliperidone Palmitate 6 Month formulation for the Treatment of Patients with subjects schizophrenia (a type of mental disorder or illness characterized by abnormal social behavior and failure to understand what is real).MedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2017-001941-28-ESJanssen-Cilag International NV838
进行中（未招募）
1 期
Study of Paliperidone Palmitate 6 Month formulation for the Treatment of Patients with subjects schizophrenia (a type of mental disorder or illness characterized by abnormal social behavior and failure to understand what is real).SchizophreniaEUCTR2017-001941-28-PLJanssen-Cilag International NV841